The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial-Reference-Cited by-同舟云学术

The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial

Published:2007-04-01 Issue:4 Volume:92 Page:1305-1310
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Grey Andrew¹,Bolland Mark¹,Gamble Greg¹,Wattie Diana¹,Horne Anne¹,Davidson James²,Reid Ian R.¹

Affiliation:

1. Department of Medicine (A.G., M.B., G.G., D.W., A.H., I.R.R.), University of Auckland, Auckland City Hospital, 1020 Auckland, New Zealand

2. LabPlus (J.D.), Auckland City Hospital, 1020 Auckland, New Zealand

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/92/4/1305/9052641/jcem1305.pdf

Reference44 articles.

1. Thiazolidinediones.;Yki-Jarvinen;N Engl J Med,2004

2. Thiazolidinediones: the case for early use.;Kendall;Diabetes Care,2006

3. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.;Dormandy;Lancet,2005

4. The PROactive study: some answers, many questions.;Yki-Jarvinen;Lancet,2005

5. Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.;Gimble;Mol Pharmacol,1996

Cited by 367 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone Health in Patients With Type 2 Diabetes;Journal of the Endocrine Society;2024-05-23

2. Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures;Medicina;2024-02-26

3. The association between anti-diabetic agents and osteoporosis, sarcopenia, and osteosarcopenia among Iranian older adults; Bushehr Elderly Health (BEH) program;DARU Journal of Pharmaceutical Sciences;2023-12-22

4. Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes;Diabetes, Metabolic Syndrome and Obesity;2023-12

5. A simple fragility fracture risk score for type 2 diabetes patients: a derivation, validation, comparison, and risk stratification study;European Journal of Endocrinology;2023-11